Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma
Jan A. Burger(The University of Texas MD Anderson Cancer Center), Nicholas Chiorazzi(Feinstein Institute for Medical Research), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Marc K. Hellerstein(Washington University in St. Louis), Shih‐Shih Chen(Feinstein Institute for Medical Research), Kelvin W. Li(KineMed (United States)), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Annette Jalayer(The University of Texas MD Anderson Cancer Center), Claire Emson, Mariela Sivina(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Xiao‐Jie Yan, Scott Turner(KineMed (United States))
Cited by 11
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k